MedTrace Logo

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

NCT07283692 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2026-05-13

No results posted yet for this study

Summary

This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.

Conditions

Interventions

DRUG

Serplulimab

1.5mg/kg qw, start from C1D15

DRUG

Paclitaxel

80mg/m\^2 qw

DRUG

Carboplatin

AUC=1.5, D1, 8, 15, every 28 days

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Wenjin Yin, M.D. · Renji Hospital,School of Medicine, Shanghai Jiaotong University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2026-12-31
Completion
2031-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07283692 on ClinicalTrials.gov